FI940681A - Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin - Google Patents

Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin Download PDF

Info

Publication number
FI940681A
FI940681A FI940681A FI940681A FI940681A FI 940681 A FI940681 A FI 940681A FI 940681 A FI940681 A FI 940681A FI 940681 A FI940681 A FI 940681A FI 940681 A FI940681 A FI 940681A
Authority
FI
Finland
Prior art keywords
moraxella catarrhalis
omps
proteins
methods
variants
Prior art date
Application number
FI940681A
Other languages
English (en)
Swedish (sv)
Other versions
FI940681A0 (fi
FI106844B (fi
Inventor
Eric J Hansen
Merja Helminen
Isobel Maciver
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of FI940681A0 publication Critical patent/FI940681A0/fi
Publication of FI940681A publication Critical patent/FI940681A/fi
Application granted granted Critical
Publication of FI106844B publication Critical patent/FI106844B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI940681A 1991-08-15 1994-02-14 Menetelmä Moraxella catarrhalisin antigeeneihin liittyvien koostumusten ja vasta-aineiden valmistamiseksi sekä DNA-segmentti, yhdistelmävektori ja yhdistelmäisäntäsolu FI106844B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74559191 1991-08-15
US07/745,591 US5552146A (en) 1991-08-15 1991-08-15 Methods and compositions relating to useful antigens of Moraxella catarrhalis
PCT/US1992/006869 WO1993003761A1 (en) 1991-08-15 1992-08-14 METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)
US9206869 1992-08-14

Publications (3)

Publication Number Publication Date
FI940681A0 FI940681A0 (fi) 1994-02-14
FI940681A true FI940681A (fi) 1994-04-07
FI106844B FI106844B (fi) 2001-04-30

Family

ID=24997358

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940681A FI106844B (fi) 1991-08-15 1994-02-14 Menetelmä Moraxella catarrhalisin antigeeneihin liittyvien koostumusten ja vasta-aineiden valmistamiseksi sekä DNA-segmentti, yhdistelmävektori ja yhdistelmäisäntäsolu

Country Status (14)

Country Link
US (3) US5552146A (fi)
EP (1) EP0612250B1 (fi)
JP (1) JP3499868B2 (fi)
KR (1) KR100271888B1 (fi)
AT (1) ATE140627T1 (fi)
AU (1) AU666329B2 (fi)
CA (1) CA2115565C (fi)
DE (1) DE69212495T2 (fi)
DK (1) DK0612250T3 (fi)
ES (1) ES2092696T3 (fi)
FI (1) FI106844B (fi)
GR (1) GR3021423T3 (fi)
NO (2) NO308413B1 (fi)
WO (1) WO1993003761A1 (fi)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
KR100500000B1 (ko) * 1996-05-03 2005-12-12 안텍스 바이오로직스 인코퍼레이션 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도
US6004562A (en) * 1996-08-16 1999-12-21 The Research Foundation Of The State University Of New York Outer membrane protein B1 of Moraxella catarrhalis
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
EP0948625B1 (en) 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
US6627728B1 (en) 1998-05-12 2003-09-30 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) * 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2425855A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
LT3017827T (lt) 2005-12-22 2019-01-10 Glaxosmithkline Biologicals S.A. Pneumokokinė polisacharidinė konjuguota vakcina
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
KR20100045445A (ko) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
AU2009262893B2 (en) 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
JP7291633B2 (ja) 2017-05-30 2023-06-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アジュバントを製造する方法
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030556A (en) * 1989-03-30 1991-07-09 Danielle Beaulieu Species-specific DNNA probe for the detection of Branhamella catarrhalis

Also Published As

Publication number Publication date
US5759813A (en) 1998-06-02
NO308413B1 (no) 2000-09-11
US5552146A (en) 1996-09-03
FI940681A0 (fi) 1994-02-14
WO1993003761A1 (en) 1993-03-04
NO20002413D0 (no) 2000-05-09
FI106844B (fi) 2001-04-30
NO20002413L (no) 2000-05-09
CA2115565A1 (en) 1993-03-04
ES2092696T3 (es) 1996-12-01
JPH07501210A (ja) 1995-02-09
DE69212495D1 (de) 1996-08-29
DE69212495T2 (de) 1997-03-06
JP3499868B2 (ja) 2004-02-23
ATE140627T1 (de) 1996-08-15
EP0612250A1 (en) 1994-08-31
AU2487892A (en) 1993-03-16
EP0612250B1 (en) 1996-07-24
US5599693A (en) 1997-02-04
DK0612250T3 (da) 1996-11-25
GR3021423T3 (en) 1997-01-31
NO940502D0 (no) 1994-02-14
NO940502L (no) 1994-03-28
AU666329B2 (en) 1996-02-08
CA2115565C (en) 2007-08-07
KR100271888B1 (ko) 2000-11-15

Similar Documents

Publication Publication Date Title
FI940681A (fi) Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin
PT100781A (pt) Sequencias de dna codificadoras de proteinas de superficie externa, proteinas contendo as referidas sequencias, obtidas a partir de borrelia burgdorferi, e vacinas contendo as referidas proteinas
ATE497004T1 (de) Moraxella catarrhalis antigene uspa1 und uspa2
NO976119L (no) OMP26-antigen fra Haemophilus influenzae
DE69331901D1 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
FI924457A0 (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
DK482788D0 (da) Vacciner mod og diagnostiske bestemmelser af haemophilus influenzae
YU12991A (sh) Rekombinantne vakcine protiv kokcidioze-5-7 eimeria površinski antigen
ATA171686A (de) Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
AU5625796A (en) Protective epitopes of adenyl cyclase-haemolysin(AC-Hly), their application to the treatment or to the prevention of bordetella infections
ATE154244T1 (de) Induzierung eines schutzes gegen virale infektionen
DE69119785D1 (de) Zweiphasensystem zur herstellung und präsentation von fremdantigenen in hybriden lebendimpfstoffen
WO1996034884A3 (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparation and use
ATE103817T1 (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobulin-g-haeltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen.
Ha Use of Monoclonal Antibodies against Infectious Agent